Present Study | |||||||
---|---|---|---|---|---|---|---|
Chr. | Genes | Type of alteration | Clinical association | References | Primary Tumor | Recurrence | SPT |
3p21.31 | SEMA3F | Loss | High metastasis and poor survival | [14] | No | Yes | Yes |
3p22.2 | MLH1 | Loss | Early stages of disease | [15] | Yes | Yes | Yes |
3p14.2 | FHIT | Loss | Early Event | [16] | No | Yes | No |
3q26.32 | PIK3CA | Gain | Poor prognosis | No | No | Yes | |
3q26.33 | SOX2 | Gain | Metastasis,worse outcome, resistance to cisplatin | [19] | No | Yes | No |
4q32.3 | PALLD | LOH | Poor survival | [20] | No | Yes | No |
4q32.3 | DDX60L | LOH | Poor survival | [20] | No | Yes | No |
4q35.2 | ING2 | LOH | Advanced stage | [21] | Yes | Yes | No |
4q35.2 | FAT1 | LOH | Advanced tumour stage | [22] | No | Yes | No |
7p11.2 | EGFR | Gain | Poor prognostic | [23] | No | Yes | Yes |
9p21.3 | CDKN2A | Loss | High frequency of recurrences; early event in HNSCC progression | [24] | No | Yes | Gain |
9p21.3 | CDKN2B | Loss | Early event in HNSCC progression | [25] | No | Yes | Gain |
11q13.3 | FADD | Gain | Worse disease-specific survival | [26] | No | Yes | Yes |
11q13.3 | ANO1 | Gain | Poor overall survival, metastases | No | Yes | Yes | |
11q13.3 | CTTN | Gain | Lymph node metastasis | [29] | No | Yes | Yes |
11q13.3 | CCND1 | Gain | Presence of occult lymph node metastases, advanced clinical stage and shorter survival | No | Yes | Yes | |
11q21 | MRE11A | Loss | Reduced sensitivity to ionizing radiation in HNSCC | [32] | No | No | Yes |
11q22.3 | ATM | Loss | Reduced sensitivity to ionizing radiation in HNSCC | [32] | Yes | Yes | Yes |
11q23.3 | H2AFX | Loss | Reduced sensitivity to ionizing radiation in HNSCC | [32] | Yes | Yes | Yes |
13q13.1 | BRCA2 | LOH | Poor patient outcome | [33] | Yes | Yes | Yes |
13q14.2 | RB1 | LOH | Poor patient outcome | [33] | Yes | Yes | Yes |
17p13.1 | TP53 | Loss | Nonresponse to neoadjuvant chemotherapy | [34] | Yes | Yes | Yes |
18q21.2 | SMAD4 | Loss | Advanced stage and poor prognosis | [35] | No | Yes | No |
18q23 | GALR1 | Methylation | Advanced stage and poor prognosis | No | Loss | No | |
22q13.2 | CYB5R3 | Loss | Worse prognosis, decreased survival | [38] | Yes | No | No |